Total
0
Shares
DIAGNOS (TSXV:ADK) enters exclusive distribution agreement to reach European markets
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Diagnos (ADK, DGNOF) has announced an exclusive distribution agreement with Diagnos Europe to access the DACH countries in Europe
  • The agreement will help the company tap into the most important European regions for the optical market
  • This market access will give the company the potential to reach over 140 million people
  • Combined with the company's AI technology and networks in Europe, Diagnos will have the opportunity to access patients who are at risk of losing their vision due to diabetes
  • Europe is the region in the world with the largest population of diabetics between the ages 0-14, and 20-79
  • Shares of Diagnos dipped 1.85 per cent to C$0.53 as of 2:14 p.m. EDT

Diagnos (ADK) has entered into an agreement with Diagnos Europe in order to access the most significant region optical market in Europe — DACH countries.

The DACH countries — which stands for  Deutschland (Germany),  Austria, and Confoederatio Helvetica (Switzerland) — is one of the most notable optical industries in Europe, while diabetics in these countries are estimated to number roughly 10 million out of 140 million.

The company's goal is to be able to access and serve individuals who are at risk of losing their vision due to diabetes through its artificial intelligence (AI) technology.

"Diagnos complies with the highest standards in terms of delivering precision results and in real-time, so the referral of patients is done effectively," André Larente, CEO of Diagnos, said in a release. 

"Our AI technology enhances the experience of the patient and our indications show that at least 9 per cent of referrals will be sent to the specialists so they can be treated properly."

With its headquarters in Brossard, Quebec, Diagnos is a company focused on the early detection of critical health care problems through its FLAIRE AI platform. 

The platform allows for the modification and development of applications, including computer-assisted retina analysis (CARA), which is an AI-based image enhancement algorithm that provides sharper, clearer and easier-to-analyze retinal images.

Following the announcement, shares of Diagnos dropped 1.85 per cent to C$0.53 as of 2:14 p.m. EDT.

More From The Market Herald
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

" Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.
VitalHub (TSXV:VHI) signs multi-year contract with Hampshire Hospitals NHS Foundation Trust

" Skylight Health Group (TSXV:SLHG) acquires Pennsylvania Clinic Group

Skylight Health Group Inc. (SLHG) executes the definitive agreements to acquire a controlling interest in Aspire Health Concepts, Inc.